{"product_id":"jnj-ansoff-matrix","title":"Johnson \u0026 Johnson Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Johnson \u0026amp; Johnson Amsoff Matrix Analysis shows how the company can grow through market penetration, market development, product development, and diversification. This page already includes a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeepen Darzalex in multiple myeloma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDarzalex remained Johnson \u0026amp; Johnson's anchor hematology asset in 2025, with annual sales above $10 billion. Johnson \u0026amp; Johnson is still moving it into earlier multiple myeloma lines and pushing the subcutaneous version, Darzalex Faspro, to widen share in a crowded market. Earlier use usually means longer treatment duration, more physician familiarity, and higher switching costs, which helps defend franchise value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroaden Tremfya across immunology indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson is broadening Tremfya across three immunology uses: plaque psoriasis, psoriatic arthritis, and ulcerative colitis. That turns one dermatology brand into a multi-specialty asset, raising wallet share in the same payer and physician accounts. It also gives Johnson \u0026amp; Johnson a cleaner growth path as legacy brands like Stelara face 2025 biosimilar pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDefend lung cancer share with Rybrevant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s 2024 first-line approval for EGFR-mutated NSCLC lifted Rybrevant plus Lazcluze into a large, crowded market where lung cancer made up about 12% of all new global cancers in 2022. EGFR mutations drive roughly 10% to 15% of NSCLC cases in Western patients, so the prize is share, not a new market. That is classic penetration: defend the same oncology base with a differentiated regimen.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCross-sell Abiomed and Shockwave together\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson used Abiomed and Shockwave Medical to sell more cardiovascular tools into the same hospital accounts, pushing deeper into cath labs and operating rooms. The $13.1 billion Shockwave Medical deal in 2024 added intravascular lithotripsy to Abiomed’s existing pump base, so one sales team can target more of each hospital’s device spend. That is market penetration: higher wallet share from the same customers, not just a bigger customer count.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMonetize the MedTech installed base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn fiscal 2025, Johnson \u0026amp; Johnson's MedTech base still spans surgery, orthopedics, and vision, with about $32 billion in sales and a large installed base. It can lift market penetration by bundling instruments, capital equipment, and consumables around the same operating room, which makes buying easier for hospitals. That mix boosts recurring revenue and raises switching costs, so account share can grow without a new product launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJohnson \u0026amp; Johnson Deepens Share in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s market penetration in 2025 came from deeper share in existing accounts, not new markets. Darzalex topped $10 billion in sales, Tremfya expanded across three uses, and Rybrevant plus Lazcluze targeted EGFR-mutated NSCLC, a niche within a crowded lung cancer field. In MedTech, Abiomed plus Shockwave Medical widened wallet share across the same hospital customers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 driver\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarzalex\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$10B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTremfya\u003c\/td\u003e\n\u003ctd\u003e3 indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShockwave deal\u003c\/td\u003e\n\u003ctd\u003e$13.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a strategic overview of Johnson \u0026amp; Johnson’s growth options across existing and new products and markets\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a fast, clear Johnson \u0026amp; Johnson Ansoff Matrix view to quickly spot growth priorities and reduce strategic planning friction.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand existing drugs into more countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson uses market development by taking existing oncology and immunology brands into Europe, Japan, and other markets. It operates in about 175 countries, so each new approval can add sales without funding a new molecule. That works best for drugs with long patent lives and broad clinical demand, because launch risk is lower and revenue can scale faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMove MedTech into ambulatory surgery centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson can push more orthopedics and surgery volume into ambulatory surgery centers because the same implants and instruments work in lower-cost outpatient sites. That matters as the U.S. keeps shifting procedures out of inpatient hospitals: Medicare paid for 6,500-plus ASCs in 2025, and CMS kept adding covered outpatient procedures.\u003c\/p\u003e\n\u003cp\u003eSo the addressable market grows without changing core product design, while Johnson \u0026amp; Johnson benefits from broader site-of-care adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrow cardiovascular devices outside the United States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGrow cardiovascular devices outside the United States by using Shockwave and Abiomed to push deeper into catheter labs in Europe and Asia-Pacific. International use of advanced cardiovascular intervention is still uneven, so geography is a clear growth lever for Johnson \u0026amp; Johnson. Selling proven devices into new regions is lower risk than building a new platform from scratch, and it can scale faster once local approvals and hospital adoption line up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUse China, India, and Latin America\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson can push existing medicines and devices across China, India, and Latin America, where the patient base is huge: India has about 1.46 billion people, China about 1.41 billion, and Latin America about 660 million. That adds volume even if US and Europe slow. The main risk is not demand, but slow approvals and uneven reimbursement, which can delay sales and cap margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWin more payer and formulary access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s market development is also access expansion inside the same country: each new health-system or payer contract can open millions of covered lives for already proven therapies and devices. In 2025, Medicare Part D alone covered about 53 million people, so better formulary placement can lift volume fast without new clinical risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJohnson \u0026amp; Johnson’s global reach can turn each launch into fast revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s market development means selling approved drugs and devices in more countries, not inventing new ones. With operations in about 175 countries, each new launch can add revenue fast, especially in oncology, immunology, and cardiovascular care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLevers\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeography\u003c\/td\u003e\n\u003ctd\u003e175 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite shift\u003c\/td\u003e\n\u003ctd\u003e6,500+ ASCs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage\u003c\/td\u003e\n\u003ctd\u003e53 million Part D lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eChina, India, and Latin America also widen demand, but approvals and reimbursement still set the pace.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eJohnson \u0026amp; Johnson Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Johnson \u0026amp; Johnson Amsoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report, so what you see here is exactly what you’ll get. Purchase unlocks the complete, detailed version immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance nipocalimab in autoimmune disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson is advancing nipocalimab in autoimmune disease as a key late-stage immunology bet, with Phase 3 studies targeting FcRn-mediated disease. The asset could broaden Johnson \u0026amp; Johnson’s branded portfolio in a high-value specialty space if regulators approve it in 2025 or later.\u003c\/p\u003e\n\u003cp\u003eFcRn blockade is clinically important because it lowers pathogenic IgG autoantibodies without broad immune suppression, which matters in diseases like myasthenia gravis and Sjögren's disease. That gives Johnson \u0026amp; Johnson a shot at first-mover scale in a category with strong pricing power.\u003c\/p\u003e\n\u003cp\u003eFor an Ansoff Matrix view, this is product development: a new therapy for an existing immunology base. The upside is clear, but launch value still depends on Phase 3 readouts, label scope, and uptake versus entrenched specialty rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuild icotrokinra as an oral immunology option\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Johnson \u0026amp; Johnson is building icotrokinra as an oral next-gen option for psoriasis and inflammatory bowel disease, which fits a product-development move into higher-convenience immunology. Oral therapy can beat injectable biologics on ease of use, and that matters in chronic care where adherence drives outcomes. It also gives Johnson \u0026amp; Johnson a cleaner shot at share in a market with strong patient preference for pills.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialize Rybrevant plus Lazcluze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson turned Rybrevant plus Lazcluze into a new first-line platform for EGFR-mutated non-small cell lung cancer. In MARIPOSA, the regimen cut the risk of disease progression or death by 30% versus osimertinib and lifted median progression-free survival to 23.7 months from 16.6 months. That is product development: it adds a new therapy construct to an existing oncology market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRefresh MedTech with next-gen device launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025, Johnson \u0026amp; Johnson kept refreshing MedTech with new launches in minimally invasive surgery, electrophysiology, and cardiovascular care. That matters because MedTech already brought in about $32B in annual sales, so each launch can add revenue without starting from zero. It also helps Johnson \u0026amp; Johnson defend share against smaller device peers that move faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvest in robotics and digital surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2025, Johnson \u0026amp; Johnson kept pushing robotics and digital surgery to refresh its surgical franchise. This fits Ansoff matrix product development: better precision, software, and analytics can lift outcomes and add recurring revenue. It also matches hospital demand for shorter operating-room times and fewer complications.\u003c\/p\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson can use this to defend share in MedTech, where faster workflows matter as much as the device itself. The strategy is strongest when robotics is paired with data tools that make each case more useful for surgeons and hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJohnson \u0026amp; Johnson's 2025 product pipeline targets existing markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Johnson \u0026amp; Johnson’s product development in Ansoff Matrix terms centers on late-stage launches like nipocalimab, icotrokinra, and Rybrevant plus Lazcluze, all aimed at existing immunology and oncology markets. This is new product, not new market, growth, with Phase 3 data and label scope driving value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRybrevant plus Lazcluze\u003c\/td\u003e\n\u003ctd\u003e23.7 vs 16.6 mo PFS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedTech\u003c\/td\u003e\n\u003ctd\u003eAbout $32B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnter structural heart through V-Wave\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson's V-Wave deal pushes into structural heart with an interatrial shunt for advanced heart failure, a field outside its surgery and orthopedics base. Advanced heart failure affects about 6.2 million adults in the U.S., so the addressable need is large. It is diversification because it adds a new device type and a new physician user group. If scaled, it can widen Johnson \u0026amp; Johnson's cardiovascular franchise beyond established catheter tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnter intravascular lithotripsy with Shockwave\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShockwave Medical gave Johnson \u0026amp; Johnson a new calcium-modification therapy class in intravascular lithotripsy, which uses sonic pressure waves to crack calcium before stent or balloon placement. Johnson \u0026amp; Johnson bought Shockwave for about $13.1 billion in 2024, adding an adjacent market with different procedural use than its older cardiovascular products. That widens Johnson \u0026amp; Johnson's MedTech reach beyond standard stents and balloons into a higher-value niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuild a broader cardiovascular platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe $13.1 billion Shockwave deal and V-Wave, valued at up to $1.7 billion, show Johnson \u0026amp; Johnson building a broader cardiovascular platform. With biomed, Shockwave, and V-Wave, Johnson \u0026amp; Johnson now spans acute support, calcium treatment, and structural heart failure, instead of relying on one device class. That mix lowers exposure to any single procedure type and can spread revenue risk across more parts of the cath lab.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand beyond legacy pharmaceutical mechanisms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson is diversifying at the molecule level by moving beyond legacy biologics into FcRn inhibition and oral IL-23 blockade. These newer mechanisms widen the scientific base and reduce reliance on older drug classes while staying inside healthcare.\u003c\/p\u003e\n\u003cp\u003eThat matters in 2025 because Johnson \u0026amp; Johnson still leans on a few big franchises, so a broader mix of targets can lower concentration risk and support longer pipeline depth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUse the Intra-Cellular Therapies deal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s 2025 acquisition of Intra-Cellular Therapies is a clear diversification move in the Ansoff Matrix: it adds Caplyta and gives Johnson \u0026amp; Johnson a real entry into central nervous system care. The deal, valued at about $14.6 billion, brings a $1 billion-plus asset into a new therapeutic area. That makes it a strong example of new-market, new-product diversification in Johnson \u0026amp; Johnson’s current portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJohnson \u0026amp; Johnson’s 2025 deals widen its reach beyond surgery and orthopedics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson’s 2025 diversification moves add new products and new care settings, not just more of the same. The Intra-Cellular Therapies deal, valued at about $14.6 billion, brings Caplyta into central nervous system care, while Shockwave Medical for $13.1 billion and V-Wave expand cardiovascular reach. That broadens revenue beyond core surgery and orthopedics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDeal\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eNew area\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntra-Cellular Therapies\u003c\/td\u003e\n\u003ctd\u003e$14.6B\u003c\/td\u003e\n\u003ctd\u003eCNS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShockwave Medical\u003c\/td\u003e\n\u003ctd\u003e$13.1B\u003c\/td\u003e\n\u003ctd\u003eCardio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53648800940374,"sku":"jnj-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/jnj-ansoff-analysis.webp?v=1778888775","url":"https:\/\/balancedscorecardexamples.com\/products\/jnj-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}